References
- Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–936.
- Pozzilli C, Pugliatti M. An overview of pregnancy-related issues in patients with multiple sclerosis. E J Neuro. 2015;22(Suppl 2):34–39.
- European Medicines Agency (EMA)Evaluation of Medicines for Human Use. Guideline on risk assessment of medical products on human reproduction and lactation: from data to labeling. London 24 July 2008; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003307.pdf
- Jalkanen A, Alanen A, Airas L. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler. 2010;16(8):950–955.
- Nielsen NM, Jorgensen KT, Stenager E, et al. Reproductive history and risk of multiple sclerosis. Epidemiology (Cambridge, Mass). 2011;22(4):546–552.
- Safarinejad MR. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis. J Neuroendocrinol. 2008;20(12):1368–1375.
- Lombardi G, Celso M, Bartelli M, et al. Female sexual dysfunction and hormonal status in multiple sclerosis patients. J Sex Med. 2011;8(4):1138–1146.
- Thone J, Kollar S, Nousome D, et al. Serum anti-Mullerian hormone levels in reproductive-age women with relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(1):41–47.
- Sepulveda M, Ros C, Martinez-Lapiscina EH, et al. Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: a pilot study. Mult Scler. 2016;22(4):564–568.
- Thone J, Kleiter I, Stahl A, et al. Relevance of endoglin, IL-1alpha, IL-1beta and anti-ovarian antibodies in females with multiple sclerosis. J Neurol Sci. 2016;362:240–243.
- Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immuno. 2013;149(2):219–224.
- Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124(6):1157–1168.
- Hellwig K, Brune N, Haghikia A, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008;118(1):24–28.
- Dahl J, Myhr KM, Daltveit AK, et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005;65(12):1961–1963.
- Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain: a J Neuro. 2004;127(Pt 6):1353–1360.
- Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. New Eng J Med. 1998;339(5):285–291.
- Pasto L, Portaccio E, Ghezzi A, et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol. 2012;12:165.
- Bay Bjorn AM, Ehrenstein V, Hundborg HH, et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21(2):73–80.
- Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.
- Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2004;115(1):3–9.
- Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: a case report and guidelines for performing plasma exchange in a pregnant patient. J Clin Apher. 2016.2016 May 3. doi: 10.1002/jca.21468. [Epub ahead of print]
- Salemi G, Callari G, Gammino M, et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand. 2004;110(1):23–26.
- Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler. 2014;20(6):739–746.
- Finkelsztejn A, Brooks JB, Paschoal FM Jr., et al. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG: an Int J Obstetrics Gynaecol. 2011;118(7):790–797.
- Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247–253.
- Paavilainen T, Kurki T, Parkkola R, et al. Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. E J Neuro. 2007;14(11):1216–1221.
- Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2013;115(2):154–159.
- From the American Academy of Pediatrics. Breastfeeding and the use of human milk.Section on breastfeeding. Pediatrics. 2012;129(3):e827–41.
- Almas S, Vance J, Baker T, et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458.
- Portaccio E, Ghezzi A, Hakiki B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85(8):845–850.
- Hellwig K, Rockhoff M, Herbstritt S, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol. 2015;72(10):1132–1138.
- Pakpoor J, Disanto G, Lacey MV, et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol. 2012;259(10):2246–2248.
- Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009;66(8):958–963.
- Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology. 2011;77(2):145–150.
- Tasnif Y, Morado J, Hebert MF. Pregnancy-related pharmacokinetic changes. Clin Pharmacol Ther. 2016;100(1):53–62.
- Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet. 1990;18(1):20–36.
- Odutayo A, Hladunewich M. Obstetric nephrology: renal hemodynamic and metabolic physiology in normal pregnancy. Clin Journal Am Soc Nephrology: CJASN. 2012;7(12):2073–2080.
- Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.
- Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reproduct Immuno. 1996;36(5):248–255.
- Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–895.
- Debbage P, Thurner GC. Nanomedicine faces barriers. Pharmaceuticals (Basel). 2010;3(11):3371–3416.
- Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci. 2007;259(1–2):27–37.
- Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety. 2001;24(13):979–990.
- EMA. Copaxone® (glatiramer acetate) - EPAR summary of product characteristics 2013 Available from: http://www.tevauk.com/mediafile/id/15860.pdf.
- Fragoso YD, Finkelsztejn A, Comini-Frota ER, et al. Pregnancy and multiple sclerosis: the initial results from a Brazilian database. Arq Neuropsiquiatr. 2009;67(3a):657–660.
- Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15(9):1037–1042.
- Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–1135.
- Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12:124.
- Finkelsztejn A, Fragoso YD, Ferreira ML, et al. The Brazilian database on pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2011;113(4):277–280.
- Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010;257(4):580–583.
- Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010;257(12):2020–2023.
- Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. CNS Drugs. 2010;24(11):969–976.
- Fernandez Liguori N, Klajn D, Acion L, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). Mult Scler. 2009;15(5):555–562.
- Hellwig K, Beste C, Schimrigk S, et al. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord. 2009;2(1):7–11.
- Neudorfer O, Sandberg-Wollheim M, Coyle PK, et al. The glatiramer acetate pregnancy database. ECTRIMS Online Lib. 2015 October 7;116357:P1507.
- Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler. 2016;22(6):810–816.
- Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol. 2011;258(3):502–503.
- EMA. Avonex® (interferon beta-1a) - EPAR summary of product characteristics 2007 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdf.
- EMA. Rebif® (interferon beta-1a) - EPAR summary of product characteristics 2008 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf.
- EMA. Betaferon® (interferon beta-1b) - EPAR summary of product characteristics 2006 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf.
- EMA. Plegridy® (peginterferon beta-1a) - EPAR summary of product characteristics 2014 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002827/WC500170302.pdf.
- Thiel S, Langer-Gould A, Rockhoff M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis – a prospective cohort study from the German multiple sclerosis and pregnancy registry. Mult Scler. 2016;22(6):801–809.
- Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011;17(4):423–430.
- Hale TW, Siddiqui AA, Baker TE. Transfer of interferon beta-1a into human breastmilk. Breastfeeding Med: Official J Acad Breastfeeding Med. 2012;7(2):123–125.
- Langer-Gould AM. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014;82(8):654–655.
- Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62(5):1494–1503.
- Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Therapy. 2014;3(2):133–138.
- EMA. Aubagio® (teriflunomide) - EPAR summary of product characteristics 2013 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf.
- Davenport L, Beyer B, Truffinet P, et al. Nonclinical data demonstrate high sensitivity of rats versus humans to embryo-fetal toxicity when exposed to teriflunomide. London, UK: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2016 [September 14-17,].
- EMA. Tecfidera® (dimethyl fumarate) - EPAR summary of product characteristics 2014 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf.
- Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Therapy. 2015;4(2):93–104.
- Li J, Fox R, Phillip S, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and post-marketing experience (P608). 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Barcelona, Spain. 2015.
- Mendelson K, Evans T, Sphingosine HT. 1-phosphate signalling. Development. 2014;141(1):5–9.
- Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674–680.
- Geissbühler Y, Vile J, Koren G, et al. Cumulative data on pregnancy outcomes after exposure to fingolimod and in comparison with the general population. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS; London, UK. September 14-17, 2016. 2016.
- EMA. Gilenya® (fingolimod) - EPAR summary of product characteristics 2015 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf.
- Wehner NG, Shopp G, Oneda S, et al. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Devel Reproduct Toxico. 2009;86(2):117–130.
- Wehner NG, Shopp G, Osterburg I, et al. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Devel Reproduct Toxico. 2009;86(2):144–156.
- Wehner NG, Shopp G, Rocca MS, et al. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Devel Reproduct Toxico. 2009;86(2):98–107.
- Friend S, Richman S, Bloomgren G, et al. Evaluation of pregnancy outcomes from the Tysabri(R) (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150.
- Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–963.
- Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Multi Sclerosis. 2015;21(2):198–205.
- Portaccio E. Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis. ECTRIMS Online Lib. 2014 Oct;11:64544.
- Ciron J, Hautecoeur P, Mathis S, et al. Natalizumab throughout pregnancy: risk of low platelet count in the newborn at delivery. Rev Neurol (Paris). 2016;172(2):165–166.
- Fagius J, Burman J. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand. 2014;129(6):e27–9.
- Bayas A, Penzien J, Hellwig K. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis. Acta Neurol Scand. 2011;124(4):290–292.
- Hoevenaren IA, De Vries LC, Rijnders RJ, et al. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand. 2011;123(6):430–433.
- Baker TE, Cooper SD, Kessler L, et al. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Human Lac: J Int Lac Cons Assoc. 2015;31(2):233–236.
- Rigau V, Mania A, Befort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology. 2012;79(22):2214–2216.
- Hellwig K, Gold R, Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology. 2011;7615:1362–1363. author reply 3.
- De Giglio L, Gasperini C, Tortorella C, et al. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand. 2015;131(5):336–340.
- EMA. Lemtrada® (alemtuzumab) - EPAR summary of product characteristics 2013 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf.
- Achiron A, Chambers C, Fox EJ, et al. Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Barcelona, Spain. 2015.
- Yarur A, Kane SV. Update on pregnancy and breastfeeding in the era of biologics. Diges Liver Dis: Official J Italian Soc Gastroentero Italian Assoc Study Liver. 2013;45(10):787–794.
- Gerbershagen K, Thiel S, Limmroth V, et al. Disease activity during pregnancy and pregnancy outcomes in patients with multiple sclerosis (MS) treated with alemtuzumab - a case series from the German MS and pregnancy registry. September 16, 2016, ECTRIMS Online Library. Barcelona, Spain. 2016.
- Jauniaux E, Jurkovic D, Gulbis B, et al. Materno-fetal immunoglobulin transfer and passive immunity during the first trimester of human pregnancy. Hum Reprod. 1995;10(12):3297–3300.
- Schneider H, Miller RK. Receptor-mediated uptake and transport of macromolecules in the human placenta. Int J Dev Biol. 2010;54(2–3):367–375.
- Airas L, Saraste M, Rinta S, et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2008;151(2):235–243.
- Gold R, Stefoski D, Selmaj K, et al. Pregnancy experience: nonclinical studies and pregnancy outcomes in the daclizumab clinical study program. Neurol Therapy. 2016;5(2):169–182.
- EMA. Zinbryta® (daclizumab) - EPAR summary of product characteristics 2012 [ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003862/WC500210598.pdf.
- Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950–958.
- Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–1506.
- Vaidyanathan A, McKeever K, Anand B, et al. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxico Sci: off J Soc Toxico. 2011;119(1):116–125.
- Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone. Clin Pharmaco. 1990;18(5):365–380.
- Stewart DJ, Green RM, Mikhael NZ, et al. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep. 1986;70(11):1255–1261.
- Cocco E, Sardu C, Gallo P, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler. 2008;14(9):1225–1233.
- Pecori C, Giannini M, Portaccio E, et al. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol. 2014;14:114.
- Lu E, Zhu F, Zhao Y, et al. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler. 2014;20(9):1260–1264.
- EMA. MabThera® (rituximab) - EPAR summary of product characteristics 2009 [updated 02 Aug 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf.
- Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin’s disease. J Clin Oncol: Official J Am Soc Clin Oncol. 1997;15(12):3488–3495.
- KKNMS. Qualitätshandbuch Multiple Sklerose - Empfehlungen zur Therapie der MS für Ärzte 2016 [ Available from: http://www.kompetenznetz-multiplesklerose.de/images/stories/PDF_Dateien/kknms_handbuch_gesamtausgabe_verknpft_20160914_webfrei.pdf.
- Jokubaitis VG, Spelman T, Kalincik T, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 2016;80(1):89–100.